Biosafety and Health is a leading peer-reviewed journal published by ELSEVIER, dedicated to advancing knowledge and practice in the fields of biotechnology, infectious diseases, microbiology, and public health. With an ISSN of 2096-6962 and an E-ISSN of 2590-0536, this Open Access journal has been accessible to the global research community since 2019, fostering collaboration and innovation from its base in the Netherlands. Ranked Q2 in multiple categories according to the latest metrics, including Biotechnology and Microbiology (medical), it stands as a testament to high-quality, impactful research that influences clinical and environmental practices. The journal has achieved substantial recognition in various medical fields, ranking in the 88th percentile for Public Health, Environmental and Occupational Health, and the 78th percentile for Infectious Diseases. Researchers and practitioners seeking to contribute to this evolving domain are encouraged to submit their findings, as the journal aims to promote interdisciplinary dialogue and address pressing global health challenges.

Infektsiya i Immunitet, published by the esteemed SANKT-PETERSBURG-NIIEM IMENI PASTERA, is a prominent open access journal that has been disseminating vital research findings since 2011. Focusing on the fields of immunology and infectious diseases, this journal serves as a critical platform for scholars, professionals, and students in the Russian Federation and beyond. With an ISSN of 2220-7619 and an E-ISSN of 2313-7398, it currently holds a Q4 ranking in 2023 for both Immunology and Infectious Diseases, along with notable quartile standings in related fields. Despite its emerging status, Infektsiya i Immunitet provides valuable insights and contributes to the growing discourse on immunity and infection prevention strategies, making it an essential resource for those invested in advancing knowledge and enhancing public health outcomes. Researchers can conveniently access its wealth of articles and studies that bridge theoretical understanding and practical implications in their respective domains.

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Vaccine is a premier academic journal published by Elsevier Science Ltd, dedicated to the field of vaccination and immunization research. With an impact factor and H-index that underscore its significance in the scientific community, this journal has consistently ranked in the Q1 category within various fields, including Immunology and Microbiology, Infectious Diseases, and Public Health. Since its inception in 1983, it has served as a vital resource for researchers, healthcare professionals, and students, providing rigorous peer-reviewed articles that explore important breakthroughs and innovations in vaccine development and deployment. Although it does not operate under an Open Access model, the journal maintains high visibility within academic circles, thanks to its strategic collaborations and widely respected editorial board. By bridging the gaps between laboratory discoveries and clinical applications, Vaccine plays a crucial role in advancing global health initiatives and addressing urgent public health challenges.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.